Skip to main content
. Author manuscript; available in PMC: 2016 Jul 14.
Published in final edited form as: Cell Rep. 2015 Jul 2;12(2):335–345. doi: 10.1016/j.celrep.2015.06.019

Figure 1. Purified ES-MNs exposed to mSOD1 ACM is a potent model to study non-cell autonomous MN degeneration in ALS.

Figure 1

(A) Immunocytochemical illustrations and pie charts of cultures before and after MACS® enrichment. Scale bars: 20 µm.

(B) Immunocytochemical illustrations and bar graphs of purified ES-MN numbers after 7 days exposure to non-toxic (NTg ACM) or toxic mSOD1 ACM. Scale bars: 60 µm. *Student’s t test: t[8] = 3.78, p = 0.0054.

(C) Time course of purified ES-MN loss upon exposure to ACM. ES-MNs are counted at the indicated exposure days. Lower than mSOD1 ACM at day 1 and NTg ACM at all tested days (*p < 0.05, **p < 0.01; Newman-Keuls post-hoc).

(D) At 2 days post-plating, purified ES-MNs are exposed to ACM for 1, 2, 3 or 7 days, after which medium is replaced with fresh medium and cells are cultured for an additional 6, 5, 4 or 0 day, respectively. ES-MN numbers are determined after 7 days exposures to ACM + fresh medium (FM). Bars show the number of viable ES-MNs treated with mSOD1 ACM relative to the ones treated with NTg ACM (*p < 0.01; Newman-Keuls post-hoc).

HHS Vulnerability Disclosure